Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Condition: Cancer Intervention: Biological: LVGN7409 Sponsor: Lyvgen Biopharma Holdings Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials